Based on the research results, BC patients with high expression of MAT2B and CHKB may benefit from targeted therapy against immune checkpoints with increased expression, such as CD27, CD40, HLA-DPB1, HLA-E, and HLA-DMB. This evidence concerns the gene HLA-E and breast cancer.